Description of Invention: This invention relates to the identification of a new tumor suppressor gene named Caliban from Drosophila melanogaster and Serologically determined colon cancer antigen gene 1 (Sdccag1) from humans. Sdccag1 is inactive in human lung cancer cells but active in normal lung cells. When full length Caliban or Sdccag1 is expressed in human lung cancer cells they lose their tumorigenicity. This suggests that Caliban/Sdccag1 could be used as both a therapeutic and diagnostic for cancer.
Using gene therapy to replace the inactive gene with full length Caliban/Sdccag1 to treat cancer(s).
A diagnostic assay that can determine whether the tumor suppressor Caliban/Sdccag1 gene product is functioning in cells.
Caliban/Sdccag1 can be easily adopted into already standard gene therapy applications.
Provides a novel therapeutic and diagnostic target for cancer.
It is estimated that there will be approximately 160,000 deaths caused by lung cancer in 2007. This technology will help in improving the quality of life of lung cancer patients as well as other cancers. Additionally, the gene therapy market is now a multi-million dollar industry.
Inventors: Mark A Mortin (NICHD) Xiaolin Bi (NCI)
Patent Status: HHS, Reference No. E-118-2005/0
Licensing Status: Available for licensing.
Collaborative Research Opportunity: The National Institute of Child Health and Human Development is seeking statements of capability or interest from parties interested in collaborative research to obtain pre-clinical data to be used to further develop, evaluate, or commercialize Caliban/Sdccag1 as a novel therapeutic and diagnostic target for cancer and other diseases. Please contact John D. Hewes, Ph.D. at 301-435-3121 or email@example.com for more information.
Portfolios: Cancer Cancer - Diagnostics Cancer - Therapeutics Gene Based Therapies Gene Based Therapies - Diagnostics Gene Based Therapies - Therapeutics
For Additional Information Please Contact: David Lambertson Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-4632 Fax: 301-402-0220